GENE ONLINE|News &
Opinion
Blog

Hemophilia A
FDA Approves Sanofi and Sobi’s Once-Weekly Hemophilia A Med
2023-02-23
Pfizer, Sangamo Re-Opens Enrolment For Hemophilia A Gene Therapy
2022-09-26
Sanofi’s Treatment for Hemophilia A has a Concrete FDA Decision Date
2022-08-30
Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues
2021-10-13
The Transformative Potential of Gene Therapies for Hemophilia
2021-04-08
Pfizer, Sangamo Dose First Hemophilia A Patient in Phase 3 with Gene Therapy Candidate
2020-10-08
FDA Rejects BioMarin Pharmaceuticals’ Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
2020-08-20
Sangamo’s Shares Goes up after the Announcement of Investigational Hemophilia A Gene Therapy Results
2019-07-19
Emicizumab promises weekly/biweekly prophylaxis in hemophilia-A patients
2018-09-04
LATEST
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
2023-03-22
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
2023-03-22
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
Scroll to Top